A Comprehensive Guide to Toxicology in Nonclinical Drug Development
Editat de Ali S. Faqien Limba Engleză Hardback – 21 noi 2016
Thoroughly updated to reflect the latest scientific advances and with increased coverage of international regulatory guidelines, this second edition is an essential and practical resource for all toxicologists involved in nonclinical testing in industry, academic, and regulatory settings.
- Provides unique content that is not always covered together in one comprehensive resource, including chapters on stem cells, abuse liability, biomarkers, inhalation toxicology, biostatistics, and more
- Updated with the latest international guidelines for nonclinical toxicology in both small and large molecules
- Incorporates practical examples in order to illustrate day-to-day activities and the expectations associated with working in nonclinical toxicology
Preț: 1083.93 lei
Preț vechi: 1346.94 lei
-20% Nou
Puncte Express: 1626
Preț estimativ în valută:
207.44€ • 215.48$ • 172.31£
207.44€ • 215.48$ • 172.31£
Carte tipărită la comandă
Livrare economică 27 ianuarie-10 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128036204
ISBN-10: 0128036206
Pagini: 986
Ilustrații: Approx. 300 illustrations
Dimensiuni: 216 x 276 x 55 mm
Greutate: 2.79 kg
Ediția:2. Auflage.
Editura: ELSEVIER SCIENCE
ISBN-10: 0128036206
Pagini: 986
Ilustrații: Approx. 300 illustrations
Dimensiuni: 216 x 276 x 55 mm
Greutate: 2.79 kg
Ediția:2. Auflage.
Editura: ELSEVIER SCIENCE
V-ar putea interesa
-
-19%Preț: 936.69 lei1155.48 lei -
Preț: 113.90 lei -
Human Toxicology of Chemical MixturesHarold Zeliger-5%Preț: 1997.96 lei2103.12 lei -
DNA VaccinesErin C. Donnelly-27%Preț: 1108.19 lei1519.83 lei -
-27%Preț: 1080.40 lei1481.84 lei -
Prescription DrugsJohn J. Phillips-27%Preț: 885.28 lei1215.52 lei -
FluorouracilAlberto C. Dario Longinho-27%Preț: 786.70 lei1079.65 lei -
Folic AcidMaria Szabo-27%Preț: 1106.16 lei1518.62 lei -
Authorized Generic DrugsEdward R. Nelson-27%Preț: 1417.95 lei1948.68 lei -
FDA Drug ApprovalTimothy I. King-27%Preț: 884.75 lei1215.22 lei -
RituximabGerond Lake-Bakaar-27%Preț: 958.49 lei1314.90 lei -
WasserstoffperoxidJochen Gartz-5%Preț: 84.89 lei89.36 lei
Public țintă
Toxicologists working in nonclinical drug development, toxicology professors and students, regulatory toxicologists, medical and veterinary scientistsCuprins
1. Introduction
Section I. Drug Discovery, Metabolism, and Pharmacokinetics 2. Critical Aspects of Integrated Nonclinical Drug Development: Concepts, Strategies, and Potential Pitfalls 3. ADME in Drug Discovery 4. Pharmacokinetics and Toxicokinetics
Section II. Toxicological Studies and Ind Application, and First In-Human Clinical Trial 5. Acute, Subacute, Subchronic, and Chronic General Toxicity Testing for Preclinical Drug Development 6. Genetic Toxicology Testing 7. Contemporary Practices in Core Safety Pharmacology Assessments 8. Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-In-Human Clinical Trial 9. Developmental and Reproductive Toxicology 10. Immunotoxicology Assessment in Drug Development 11. Juvenile Testing to Support Clinical Trials in Pediatric Population 12. Preclinical Evaluation of Carcinogenicity Using Standard-Bred and Genetically Engineered Rodent Models 13. Current Strategies for Abuse Liability Assessment of New Chemical Entities
Section III. Clinical Pathology, Histopathology, and Biomarkers 14. Clinical Pathology 15. Best Practice in Toxicological Pathology 16. Molecular Pathology: Applications in Nonclinical Drug Development 17. Biomarkers in Nonclinical Drug Development
IV. Biostatistics, Regulatory Toxicology, and Role of Study Directors 18. Biostatistics for Toxicologists 19. Regulatory Toxicology 20. Role of Study Director and Study Monitor in Drug Development Safety Studies
Section V. Specialty Route of Administration 21. Infusion Toxicology and Techniques 22. Photosafety Assessment
Section VI. Nonclinical Development of Monoclonal Antibodies, Stem Cells, Oncogenic and Non-Oncogenic Drugs, Oligonucleotides, and Vaccines 23. Preclinical Development of Monoclonal Antibodies 24. Nonclinical Safety Assessment of Cell-Based Therapies 25. Preclinical Development of Nononcogenic Drugs (Small and Large Molecules) 26. Preclinical Development of Oncology Drugs 27. Preclinical Toxicology of Vaccines 28. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics
Section VII. Safety Evaluation of Ocular Drugs, Botanical Products, and Medicinal Devices 29. Safety Evaluation of Ocular Drugs 30. Nonclinical Safety Assessment of Botanical Products 31. Biocompatibility Evaluation of Medical Devices
Section VIII. Predictive Toxicology, Toxicometabolomics, Toxicogenomics, and Imaging 32. Application of Evolving Computational and Biological Platforms for Chemical Safety Assessment 33. Toxicometabolomics: Technology and Applications 34. Toxicogenomics in Preclinical Development 35. Use of Imaging for Preclinical Evaluation
Section I. Drug Discovery, Metabolism, and Pharmacokinetics 2. Critical Aspects of Integrated Nonclinical Drug Development: Concepts, Strategies, and Potential Pitfalls 3. ADME in Drug Discovery 4. Pharmacokinetics and Toxicokinetics
Section II. Toxicological Studies and Ind Application, and First In-Human Clinical Trial 5. Acute, Subacute, Subchronic, and Chronic General Toxicity Testing for Preclinical Drug Development 6. Genetic Toxicology Testing 7. Contemporary Practices in Core Safety Pharmacology Assessments 8. Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-In-Human Clinical Trial 9. Developmental and Reproductive Toxicology 10. Immunotoxicology Assessment in Drug Development 11. Juvenile Testing to Support Clinical Trials in Pediatric Population 12. Preclinical Evaluation of Carcinogenicity Using Standard-Bred and Genetically Engineered Rodent Models 13. Current Strategies for Abuse Liability Assessment of New Chemical Entities
Section III. Clinical Pathology, Histopathology, and Biomarkers 14. Clinical Pathology 15. Best Practice in Toxicological Pathology 16. Molecular Pathology: Applications in Nonclinical Drug Development 17. Biomarkers in Nonclinical Drug Development
IV. Biostatistics, Regulatory Toxicology, and Role of Study Directors 18. Biostatistics for Toxicologists 19. Regulatory Toxicology 20. Role of Study Director and Study Monitor in Drug Development Safety Studies
Section V. Specialty Route of Administration 21. Infusion Toxicology and Techniques 22. Photosafety Assessment
Section VI. Nonclinical Development of Monoclonal Antibodies, Stem Cells, Oncogenic and Non-Oncogenic Drugs, Oligonucleotides, and Vaccines 23. Preclinical Development of Monoclonal Antibodies 24. Nonclinical Safety Assessment of Cell-Based Therapies 25. Preclinical Development of Nononcogenic Drugs (Small and Large Molecules) 26. Preclinical Development of Oncology Drugs 27. Preclinical Toxicology of Vaccines 28. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics
Section VII. Safety Evaluation of Ocular Drugs, Botanical Products, and Medicinal Devices 29. Safety Evaluation of Ocular Drugs 30. Nonclinical Safety Assessment of Botanical Products 31. Biocompatibility Evaluation of Medical Devices
Section VIII. Predictive Toxicology, Toxicometabolomics, Toxicogenomics, and Imaging 32. Application of Evolving Computational and Biological Platforms for Chemical Safety Assessment 33. Toxicometabolomics: Technology and Applications 34. Toxicogenomics in Preclinical Development 35. Use of Imaging for Preclinical Evaluation